OncRef

Clinical Trial: NCT01446133

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:M.D. Anderson Cancer Center
Information Provided By:M.D. Anderson Cancer Center
Last Update Posted:2026-06-23

Study Overview

Brief Summary

The goal of this clinical research study is to learn if the combination of lenalidomide and rituximab can help to control CLL. The safety of this drug combination will also be studied.

Lenalidomide is designed to change the body's immune system. It may also interfere with the development of tiny blood vessels that help support tumor growth. This may decrease the growth of cancer cells.

Rituximab is designed to attach to cancer cells and damage them, which may cause the cells to die.

Official Title

Combination of Lenalidomide and Rituximab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) as Initial Treatment or Subsequent Therapy

Conditions

Leukemia, Lymphoma

Intervention / Treatment

  • Drug: Rituximab
  • Drug: Lenalidomide

Other Study ID Numbers

  • 2011-0509
  • NCI-2012-01119

Start Date (Actual)

2011-12-12

Primary Completion Date (Estimated)

2028-06-30

Study Completion Date (Estimated)

2028-06-30

Enrollment (Estimated)

120

Study Type

Interventional

Phase

Phase 2